Elias S. Sotirchos

Are neurofilament light chain levels ready for routine clinical use? – No

Elias S. Sotirchos, Andrew J. Solomon

us (code pays fourni par la source)

Autoimmune neuroinflammation leads to neuronal death via MIF nuclease-mediated parthanatos

Jackson W. Mace, Sachin P. Gadani, Matthew D. Smith, Danny Galleguillos et autres

Central nervous system inflammation is implicated in neurodegeneration across several disorders, including multiple sclerosis (MS). While marked therapeutic progress has been made in preventing relapses in MS, primary neuroprotection in this disease remains elusive. This, in part, is due to an incomplete …

us (code pays fourni par la source)

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks

Paulus S. Rommer, Wei Jiang, Jan P. Nolte, Takahisa Mikami et autres

BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease mainly driven by aquaporin-4 antibodies (AQP4-IgG). During an attack, AQP4-IgG activates the complement system, leading to astrocyte destruction, inflammation, neuronal damage, and thus devastating and often irreversible neurologic deficits. …

at, cn, us, fr, de, jp (code pays fourni par la source)

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder

João Vitor Mahler, Gerome B. Vallejos, Takahisa Mikami, Philippe A. Bilodeau et autres

BACKGROUND AND OBJECTIVES: Double seronegative NMOSD (DS-NMOSD) lacks approved disease-modifying treatments, and limited data exist on optimal relapse-prevention strategies. In this multicenter, international, retrospective cohort study, we sought to compare the real-world effectiveness of anti-CD20 agents vs nonspecific immunosuppressants as disease-modifying strategies …

us, br, gb, ae, th, tr, cn (code pays fourni par la source)

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis

Timothy M. Miller, Merit Cudkowicz, Pamela Shaw, Angela L. Genge et autres

Importance: Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are attributable to a pathogenic variant in the superoxide dismutase 1 (SOD1) gene. Tofersen, an intrathecal antisense oligonucleotide designed to reduce SOD1 protein synthesis, is the first and only approved therapy for the …

us, gb, ca, jp, it, be, de, fr (code pays fourni par la source)

OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.

Thivya Pakeerathan, James Davis, Barbara Kornek, Gabriel Bsteh et autres

Severe optic neuritis (ON) is a common clinical manifestation in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD). Given distinct prognoses and often the necessity of early plasma exchange in NMOSD, prompt differentiation is crucial. In this study, …